Ralimetinib
Ralimetinib is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase inhibitor, it has since been reported that it acts instead as an epidermal growth factor receptor inhibitor.
A phase II trial for treatment of ovarian cancer has completed.